Skip to main content
Top
Published in: Gastric Cancer 3/2024

18-03-2024 | Gastric Cancer | Letter to the Editor

Ethnic‑specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations

Authors: Zhe Wang, Da Li, Cheng Zhang

Published in: Gastric Cancer | Issue 3/2024

Login to get access

Excerpt

We read with interest the article by Lee et al., which reported race-specific associations between body mass index (BMI) and gastric cancer (GC) in European and Korean populations [1]. This study showed a linear association between BMI and GC in people of European ancestry and a nonlinear U-shaped association between BMI and GC in people of Korean descent. However, the trial appeared to suffer from some data issues as well as methodological biases. …
Literature
Metadata
Title
Ethnic‑specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations
Authors
Zhe Wang
Da Li
Cheng Zhang
Publication date
18-03-2024
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 3/2024
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-024-01491-9

Other articles of this Issue 3/2024

Gastric Cancer 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine